Gigacloud Technology Inc vs Revolution Medicines Inc. Common Stock — how do they compare? Gigacloud Technology Inc trades at $57.21 (market cap $2.02B), while Revolution Medicines Inc. Common Stock trades at $189.32 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 20× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Revolution Medicines Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| GCT | RVMD | |
|---|---|---|
Market Cap | $2.02B | $40.32B |
Volume | 1,020,985 | 4,855,734 |
Sector | Technology | Health |
52-Week High | $56.42 | $221.15 |
52-Week Low | $25.46 | $47.50 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $2.14B | $37.02B |
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.02, up 1.89% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid profitability with 10.65% net margins and robust ROE of 32.34%. Recent news highlights institutional interest and European expansion driving growth.
Outlook remains positive with analyst consensus favoring buys (66.7%) and revenue projected to grow to $1.5B in 2026. Key risks include insider selling and competitive pressures in consumer discretionary sector. The stock trades at reasonable valuation multiples (P/E 13.44) with upside potential to consensus target of $32.50.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →